Edition:
India

AngioDynamics Inc (ANGO.OQ)

ANGO.OQ on NASDAQ Stock Exchange Global Select Market

21.42USD
1:30am IST
Change (% chg)

$-0.13 (-0.60%)
Prev Close
$21.55
Open
$21.48
Day's High
$21.75
Day's Low
$21.37
Volume
101,119
Avg. Vol
91,056
52-wk High
$23.92
52-wk Low
$15.16

Latest Key Developments (Source: Significant Developments)

AngioDynamics Q3 Earnings Per Share $0.37
Thursday, 29 Mar 2018 

March 29 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS REPORTS FISCAL 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.25.Q3 GAAP EARNINGS PER SHARE $0.37.Q3 SALES $83.9 MILLION VERSUS I/B/E/S VIEW $84.8 MILLION.Q3 EARNINGS PER SHARE VIEW $0.19 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 SALES $345 MILLION TO $350 MILLION.SEES 2018 ADJUSTED EARNINGS PER SHARE $0.70 TO $0.74.ANGIODYNAMICS - ‍ EXPECTS ITS ADJUSTED EARNINGS PER SHARE IN RANGE OF $0.64 TO $0.68, EXCLUDING ANY IMPACT FROM 2017 TAX REFORM ACT​ FOR FY 2018.FY2018 EARNINGS PER SHARE VIEW $0.71, REVENUE VIEW $346.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Angiodynamics Receives FDA Expedited Access Pathway Designation For Nanoknife System For Treatment Of Stage III Pancreatic Cancer
Thursday, 25 Jan 2018 

Jan 24 (Reuters) - Angiodynamics Inc ::ANGIODYNAMICS RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE NANOKNIFE® SYSTEM FOR THE TREATMENT OF STAGE III PANCREATIC CANCER.ANGIODYNAMICS INC - ‍FDA GRANTED EXPEDITED ACCESS PATHWAY DESIGNATION TO COMPANY'S NANOKNIFE SYSTEM​.  Full Article

AngioDynamics Says U.S. Tax Reform To Have Impact Of $0.02- $0.04 On Non-GAAP Adjusted EPS In FY 2018
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS SAYS U.S. TAX REFORM ACT TO HAVE AN IMPACT IN RANGE OF $0.02- $0.04 ON NON-GAAP ADJUSTED EPS IN FY 2018 -SEC FILING.  Full Article

AngioDynamics Q2 GAAP Earnings Per Share $0.01
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS REPORTS FISCAL 2018 SECOND QUARTER FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.16.Q2 GAAP EARNINGS PER SHARE $0.01.SEES FY 2018 SALES $345 MILLION TO $350 MILLION.Q2 SALES $86.7 MILLION VERSUS I/B/E/S VIEW $88.4 MILLION.Q2 EARNINGS PER SHARE VIEW $0.16 -- THOMSON REUTERS I/B/E/S.REAFFIRMS FY 2018 ADJUSTED EARNINGS PER SHARE VIEW $0.64 TO $0.68 EXCLUDING ITEMS.FOR 2018, COMPANY IS REDUCING ITS PREVIOUSLY ANNOUNCED NET SALES AND FREE CASH FLOW GUIDANCE.CO NOW EXPECTS ITS FISCAL YEAR 2018 NET SALES IN RANGE OF $345 TO $350 MILLION.  Full Article

AngioDynamics reports fiscal 2017 first quarter results
Wednesday, 5 Oct 2016 

AngioDynamics Inc : AngioDynamics reports fiscal 2017 first quarter results . Q1 adjusted non-GAAP earnings per share $0.17 . Q1 sales $88.1 million versus I/B/E/S view $86 million . Q1 earnings per share $0.04 . Q1 earnings per share view $0.13 -- Thomson Reuters I/B/E/S . Sees FY 2017 adjusted earnings per share $0.62 to $0.65 . FY2017 guidance remains unchanged . FY2017 earnings per share view $0.63, revenue view $358.6 million -- Thomson Reuters I/B/E/S .Sees FY 2017 sales $355 million to $360 million.  Full Article

AngioDynamics to pay $12.5 million over false claims allegations: U.S. Justice Department

WASHINGTON AngioDynamics Inc has agreed to pay the U.S. government $12.5 million to resolve allegations it caused healthcare providers to submit false claims to federal healthcare programs over the use of two medical devices, the Justice Department said on Wednesday.